Kisplyx 10 mg hard capsules

DRUG3 trials

Sponsors

AstraZeneca AB, Centre Hospitalier Universitaire De Bordeaux, Institute Of Oncology Ljubljana

Conditions

Advanced Renal Cell CarcinomaMetastatic renal cell carcinoma (mRCC) with a good or only one adverse prognostic factor intermediate risk per IMDC scorerenal cell carcinoma

Phase 1

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

Active, not recruitingCTIS2023-509604-15-00

AstraZeneca ABAdvanced Renal Cell Carcinoma

Start: 2021-02-15Target: 93Updated: 2025-11-20

Phase 2

The role of serum KIM-1 and MAdCAM-1 dynamics in early prediction of the efficacy of de-escalated systemic treatment in advanced renal cell carcinoma (STELA study).

WithdrawnCTIS2026-525749-54-00

Institute Of Oncology Ljubljanarenal cell carcinoma

Target: 150Updated: 2026-10-23

Phase 3

Strategic treatment Pause of first-line Immune Check point inhibitor + Inhibitor in good or only one adverse prognostic factor in intermediate risk metastatic renal cell carcinoma (mRCC) with an objective response: a randomized, non-inferiority phase III study - SPICI

Active, not recruitingCTIS2024-514644-93-00

Centre Hospitalier Universitaire De BordeauxMetastatic renal cell carcinoma (mRCC) with a good or only one adverse prognostic factor intermediate risk per IMDC score

Start: 2022-12-09Target: 372Updated: 2025-05-27